{"product_id":"global-immunology-partnering-2016-2023-deal-trends-players-and-financials","title":"Global Immunology Partnering 2016-2023: Deal trends, players and financials","description":"\u003cp\u003eGlobal Immunology Partnering 2016-2023: Deal trends, players and financials\u003cbr\u003e\nGlobal Immunology Partnering 2016 to 2023 provides the full collection of immunology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2016.\u003c\/p\u003e\n\n\u003cp\u003eTrends in immunology partnering deals\u003cbr\u003e\nFinancial deal terms for headline, upfront and royalty by stage of development\u003cbr\u003e\nImmunology partnering agreement structure\u003cbr\u003e\nImmunology partnering contract documents\u003cbr\u003e\nTop immunology deals by value\u003cbr\u003e\nMost active immunology dealmakers\u003c\/p\u003e\n\n\u003cp\u003eMost of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R\u0026amp;D and a commercialization of outcomes element.\u003c\/p\u003e\n\n\u003cp\u003eThe report takes readers through the comprehensive immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering immunology deals.\u003c\/p\u003e\n\n\u003cp\u003eThe report presents financial deal terms values for immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.\u003c\/p\u003e\n\n\u003cp\u003eThe initial chapters of this report provide an orientation of immunology dealmaking trends.\u003c\/p\u003e\n\n\u003cp\u003eChapter 1 provides an introduction to the report.\u003c\/p\u003e\n\n\u003cp\u003eChapter 2 provides an overview of the trends in immunology dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.\u003c\/p\u003e\n\n\u003cp\u003eChapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.\u003c\/p\u003e\n\n\u003cp\u003eChapter 4 provides a review of the leading immunology deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active immunology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.\u003c\/p\u003e\n\n\u003cp\u003eChapter 5 provides comprehensive access to immunology deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eChapter 6 provides a comprehensive directory of all immunology partnering deals by specific immunology target announced since 2016. The chapter is organized by specific immunology therapeutic target.\u003c\/p\u003e\n\n\u003cp\u003eIn addition, a comprehensive appendix is provided with each report of all immunology partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R\u0026amp;D, co-promotion, licensing etc) and technology type.\u003c\/p\u003e\n\n\u003cp\u003eThe report also includes numerous tables and figures that illustrate the trends and activities in immunology partnering and dealmaking since 2016.\u003c\/p\u003e\n\n\u003cp\u003eIn conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of immunology technologies and products.\u003c\/p\u003e\n\n\u003cp\u003eReport scope\u003c\/p\u003e\n\n\u003cp\u003eGlobal Immunology Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to immunology trends and structure of deals entered into by leading companies worldwide.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Immunology Partnering 2016 to 2023 includes:\u003c\/p\u003e\n\n\u003cp\u003eTrends in immunology dealmaking in the biopharma industry since 2016\u003cbr\u003e\nAccess to headline, upfront, milestone and royalty data\u003cbr\u003e\nAccess to hundreds of immunology deal contract documents\u003cbr\u003e\nComprehensive access to over 950 immunology deal records\u003cbr\u003e\nThe leading immunology deals by value since 2016\u003cbr\u003e\nMost active immunology dealmakers since 2016\u003c\/p\u003e\n\n\u003cp\u003eThe report includes deals for the following indications: AIDS, Allergy, Anaphylactic shock, Graft versus host disease, Inflammation, Other autoimmune, Scleroderma, Systemic lupus erythematosus, plus other immunology indications.\u003c\/p\u003e\n\n\u003cp\u003eIn Global Immunology Partnering 2016 to 2023, available deals and contracts are listed by:\u003c\/p\u003e\n\n\u003cp\u003eHeadline value\u003cbr\u003e\nUpfront payment value\u003cbr\u003e\nRoyalty rate value\u003cbr\u003e\nStage of development at signing\u003cbr\u003e\nDeal component type\u003cbr\u003e\nTechnology type\u003cbr\u003e\nSpecific therapy indication\u003c\/p\u003e\n\n\n\n\u003cp\u003eThe Global Immunology Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 950 immunology deals. Analyzing actual contract agreements allows assessment of the following:\u003c\/p\u003e\n\n\u003cp\u003eWhat are the precise rights granted or optioned?\u003cbr\u003e\nWhat is actually granted by the agreement to the partner company?\u003cbr\u003e\nWhat exclusivity is granted?\u003cbr\u003e\nWhat is the payment structure for the deal?\u003cbr\u003e\nHow are the sales and payments audited?\u003cbr\u003e\nWhat is the deal term?\u003cbr\u003e\nHow are the key terms of the agreement defined?\u003cbr\u003e\nHow are IPRs handled and owned?\u003cbr\u003e\nWho is responsible for commercialization?\u003cbr\u003e\nWho is responsible for development, supply, and manufacture?\u003cbr\u003e\nHow is confidentiality and publication managed?\u003cbr\u003e\nHow are disputes to be resolved?\u003cbr\u003e\nUnder what conditions can the deal be terminated?\u003cbr\u003e\nWhat happens when there is a change of ownership?\u003cbr\u003e\nWhat sublicensing and subcontracting provisions have been agreed?\u003cbr\u003e\nWhich boilerplate clauses does the company insist upon?\u003cbr\u003e\nWhich boilerplate clauses appear to differ from partner to partner or deal type to deal type?\u003cbr\u003e\nWhich jurisdiction does the company insist upon for agreement law?\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"June, 2023 \/ 600 Pages \/ MCW16236946","offer_id":47652339450162,"sku":null,"price":4794.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-immunology-partnering-2016-2023-deal-trends-players-and-financials","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}